FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030
|出版商||DelveInsight Business Research LLP||商品編碼||974746|
|出版日期||按訂單生產||內容資訊||英文 60 Pages
|FOSMANOGEPIX:新藥的考察與市場預測 (2030年) FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030|
|出版日期: 按訂單生產||內容資訊: 英文 60 Pages||
本報告提供現在臨床實驗中的念珠菌性菌血症治療藥物FOSMANOGEPIX的市場結構·趨勢相關分析，提供產品概要 (用法·容量，作用機制等) 和相關法規，產品開發·臨床實驗的進展，主要7個國家 (美國，歐洲5個國家 (德國，法國，義大利，西班牙，英國)，日本)的市場規模趨勢預測 (2020∼2030年)，市場競爭狀態·SWOT分析，其他的治療藥的競爭狀態，資本交易的動向，今後的市場成長可能性等調查、考察。
"FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Candidemia in 7 Major Markets. A detailed picture of the FOSMANOGEPIX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Fosmanogepix, is a novel broad-spectrum antifungal agent being evaluated in multiple clinical trials in patients with life-threatening fungal infections. Enrollment was recently completed in a Phase 2 trial evaluating the safety and efficacy of the intravenous and oral formulations of fosmanogepix for the treatment of patients with Candida infections. In that study, fosmanogepix demonstrated a high level of treatment success in the first 10 patients treated. Additional Phase 2 studies of fosmanogepix are ongoing in patients with Aspergillus and other mold infections, as well as infections caused by multi-drug-resistant Candida auris, a life-threatening fungal infection recently characterized as an "urgent" threat by the Centers for Disease Control.
Fosmanogepix has a novel mechanism of action, and its active moiety has shown broad-spectrum activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as C. auris and C. glabrata, as well as rare hard-to-treat molds including Fusarium, Scedosporium, and some fungi from the Mucorales order. Invasive fungal infections result in high mortality rates (30-80%), despite standard-of-care treatment. The frequency of fungi resistant to both the azole and echinocandin classes of drugs is increasing, and there is a significant unmet medical need for a new broad-spectrum antifungal agent.
Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for seven separate indications, and is designated as a Qualified Infectious Disease Product (QIDP) for the treatment of four indications.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of FOSMANOGEPIX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of FOSMANOGEPIX covering trial interventions, trial conditions, trial status, start and completion dates.